COMPANY NEWS

GlobeNewswire•May 22, 2019 OXNARD, Calif., May 22, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC). “Advances…

Details

Cure Pharmaceutical Secures Patent on High Loading of Active Ingredients in Oral Thin Film

GlobeNewswire•July 24, 2019 OXNARD, Calif., July 24, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using…

Details

July 24, 2019

CURE Pharmaceutical Secures Chinese Patent on its Oral Thin Films to Treat Erectile Dysfunction

GlobeNewswire•March 17, 2020 ED Drug Market Expected to Reach US$6.5B by 2025 OXNARD, Calif., March 17, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of Chinese Patent No. ZL201480039313.6. The new patent covers the loading of high amounts of active drug on an oral thin film using…

Details

March 17, 2020

CURE Pharmaceutical Receives NSF’s cGMP Certification for Dietary Supplements

GlobeNewswire•July 8, 2020 OXNARD, Calif., July 08, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical, (CURR), an innovative drug delivery and development company, today announced that its 25,000 square foot manufacturing facility has earned NSF International, cGMP certification for the manufacture of dietary supplements. This certification is issued only after extensive material and facility analysis and gives…

Details

July 8, 2020

CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

GlobeNewswire•October 1, 2019 Biopharma star brings extensive translational research experience as company advances its clinical indications OXNARD, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its chief scientific officer. In this role, Dr. Gigi will oversee all CURE’s research and…

Details

October 1, 2019

CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors

Industry veteran brings 40 year of experience to support CURE’s rapid growth OXNARD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience…

Details

November 19, 2019

CURE Pharmaceutical Named “Innovative Business of the Year” By Oxnard Chamber of Commerce

GlobeNewswire•April 26, 2019 OXNARD, Calif., April 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, has been named 2019’s Innovative Business of the Year by Oxnard Chamber of Commerce in recognition to the company’s innovative thinking for various programs, employing pioneering technology and a dedication to improving the…

Details

April 26, 2019

CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific

GlobeNewswire•February 12, 2020 Vanguard Scientific builds customer trust with CUREinside™ patented methods LOS ANGELES, Feb. 12, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction…

Details

February 12, 2020